BrightPath Biotherapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Insufficient data to determine the health of BrightPath Biotherapeutics
Key information
n/a
Debt to equity ratio
n/a
Debt
| Interest coverage ratio | n/a |
| Cash | n/a |
| Equity | n/a |
| Total liabilities | n/a |
| Total assets | n/a |
Recent financial health updates
No updates
Recent updates
In this section we usually analyse BrightPath Biotherapeutics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. BrightPath Biotherapeutics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
Financial Position Analysis
Short Term Liabilities: Insufficient data to determine if 4594's short term assets cover its short term liabilities.
Long Term Liabilities: Insufficient data to determine if 4594's short term assets cover its long term liabilities.
Debt to Equity History and Analysis
Debt Level: Insufficient data to calculate 4594's net debt to equity ratio to determine if it is satisfactory.
Reducing Debt: Insufficient data to determine if 4594's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if 4594's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if 4594's interest payments on its debt are well covered by EBIT.